CTLA4 and cancer: Interestingly, the neurological manifestations observed in the proband, especially demyelination, recapitulate some of the side effects of cancer immunotherapy using immune checkpoint inhibitors (ICIs), such as the CTLA4-blocking monoclonal antibodies ipilimumab and tremelimumab [43,44,45,46,47,48,49].